Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Agendia raises $65mm through late-stage round

Executive Summary

A year after withdrawing its IPO filing, molecular diagnostics firm Agendia BV has raised $65mm in what appears to be its Series F round. Debiopharm led and was joined by all returning backers including the Van Herk Group, ING Corporate Investments, Breedinvest, and Gilde Healthcare, along with new investors Korys (funded by the Colruyt family) and others. Proceeds will be used to fund commercialization activities for the company's Symphony suite of breast cancer tests.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies